Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2024-11-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物自愿披露关于格索雷塞片获批上市的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Yifang Bio-Technology (Shanghai) Co., Ltd. regarding the approval of a new drug (格索雷塞片) by the National Medical Products Administration. It details the drug's basic information, clinical trial results, cooperation agreements, and potential impact on the company. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is an announcement of a significant corporate event related to product approval and business impact, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is a corporate announcement about a new product approval and related business cooperation, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2024-11-11 Chinese
益方生物2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "益方生物科技（上海）股份有限公司 2024 年第三季度报告" which translates to "Yifang Biotechnology (Shanghai) Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes for the third quarter of 2024. The report explicitly states it is unaudited and covers the quarter ending September 30, 2024. The content includes comprehensive financial figures and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. There is no indication that this is an announcement of a report or a certification letter, but the full report itself. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-29 Chinese
益方生物科技（上海）股份有限公司章程（2024年10月修订）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for 益方生物科技（上海）股份有限公司 (InventisBio Co., Limited). It includes chapters on general provisions, business scope, share issuance, share transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the charter, and other governance matters. It references relevant laws and regulations such as the Company Law of the PRC, Securities Law, and Shanghai Stock Exchange rules. The content is about the internal governance structure, shareholder rights and obligations, board and management roles, share issuance and transfer rules, and procedures for shareholder meetings. It does not contain financial statements, earnings data, audit opinions, or legal proceedings updates. It is a governance document outlining the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance charter, not just an announcement or summary.
2024-10-29 Chinese
益方生物关于变更公司注册资本并修订《公司章程》的公告
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from the company Yifang Bio-Technology (Shanghai) Co., Ltd. regarding the change in registered capital and the corresponding amendment to the company's articles of association. It details the increase in share capital due to the vesting of restricted stock awards and the specific changes to the articles of association reflecting the new registered capital and total shares. The document is a formal public announcement of these corporate changes, not a full financial report or detailed management discussion. It does not contain financial statements or comprehensive financial data. The document length is short (1147 characters), and it serves as a notification of capital change and related governance document amendment. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2024-10-29 Chinese
益方生物关于召开2024年第三季度业绩说明会的公告
Call Transcript Classification · 85% confidence The document is an announcement about the scheduling and details of a 2024 third quarter earnings conference call (业绩说明会), including date, time, location, participation method, and contact information. It mentions that the company will release its 2024 Q3 report on October 30, but this document itself is not the report or transcript. It is a notice inviting investors to attend the earnings call and ask questions. The document length is short (1488 characters) and it does not contain financial data or results, only information about the upcoming call. Therefore, it is best classified as a Call Transcript announcement or related to the earnings call event. Since it is an announcement of the earnings call meeting, the closest fitting category is Call Transcript (CT), which covers full text transcripts of company conference calls or related announcements about such calls.
2024-10-25 Chinese
益方生物关于购买资产暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a purchase of assets and related party transaction by the company 益方生物科技（上海）股份有限公司. It details the transaction parties, transaction amount, approval by the board and supervisory committee, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a specific transaction, not a full financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-10-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.